autarkize | $2,502,492 | (Nov 1, 2024)
Keel | $5,933,454 | (Nov 1, 2024)
Decart | $21,000,000 | (Nov 1, 2024)
Lokavant
United States
- New York, NY
- 06/10/2023
- Unknown
- $8,000,000
Lokavant is a clinical intelligence company that improves trial execution through its data-driven analytics platform.
Lokavant’s platform helps study teams aggregate and integrate data in real-time from disparate trial data sources, and is powered by advanced analytics to proactively manage and monitor studies, surfaces insights and drive efficiencies through risk-based monitoring, operational study health tracking, trial planning and benchmarking, medical monitoring, and more.
- Industry Data Infrastructure and Analytics
- Website https://www.lokavant.com/en-us/
- LinkedIn https://www.linkedin.com/company/lokavant/about/
Related People
Rohit NambisanFounder
United States -
New York, New Yor
Trained as a neuroscientist, Rohit Nambisan is a product executive with experience leading product development organizations in pharma, medical devices, personalized medicine, health IT, healthcare data and analytics, and AI. Prior to co-founding and leading Lokavant, Rohit was most recently the Head of Digital Product at Roivant and the Head of Product at Prognos Health. Rohit holds an M.S in Management and Engineering from MIT, an M.A. in Neuroscience from Boston University, and a B.A in Cognitive Neuroscience from UC Berkeley
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MOTORMIA | $8,000,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Ataraxis AI | $4,000,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)
LINGO | $2,250,000 | (Nov 1, 2024)
ContraForce | $3,250,000 | (Nov 1, 2024)